{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:03:27Z","timestamp":1761541407280,"version":"3.40.5"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.cjca.2017.10.004","type":"journal-article","created":{"date-parts":[[2017,10,12]],"date-time":"2017-10-12T03:34:17Z","timestamp":1507779257000},"page":"31-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-6313","authenticated-orcid":false,"given":"Yaron","family":"Arbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Bennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harindra C.","family":"Wijeysundera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2017.10.004_bib1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.10.004_bib2","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/eurheartj\/ehu278","volume":"35","author":"Windecker","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.10.004_bib3","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/S0140-6736(15)60263-X","article-title":"Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials","volume":"385","author":"Palmerini","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.10.004_bib4","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1161\/CIR.0000000000000404","volume":"134","author":"Levine","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.10.004_bib5","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(14)60612-7","article-title":"Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial","volume":"384","author":"Collet","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.10.004_bib6","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.jacc.2014.09.008","article-title":"Second-generation drug-eluting stent implantation followed by 6- vs 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial","volume":"64","author":"Colombo","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib7","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2017.10.004_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2014.11.008","article-title":"6- vs 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial","volume":"65","author":"Gilard","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib9","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1161\/CIRCULATIONAHA.111.059022","article-title":"Six-month vs 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience\/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study","volume":"125","author":"Gwon","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.10.004_bib10","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A\u00a0new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation)","volume":"60","author":"Kim","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.113.003303","article-title":"Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial","volume":"129","author":"Lee","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.10.004_bib12","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.10.004_bib13","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1093\/eurheartj\/ehu523","article-title":"ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs 12 months of clopidogrel therapy after drug-eluting stenting","volume":"36","author":"Schulz-Schupke","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.10.004_bib14","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1161\/CIRCULATIONAHA.111.071589","article-title":"Short- vs long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial","volume":"125","author":"Valgimigli","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.10.004_bib15","doi-asserted-by":"crossref","first-page":"h1618","DOI":"10.1136\/bmj.h1618","article-title":"Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials","volume":"350","author":"Navarese","year":"2015","journal-title":"BMJ"},{"year":"2017","series-title":"Guidelines for the economic evaluation of health technologies","key":"10.1016\/j.cjca.2017.10.004_bib16"},{"key":"10.1016\/j.cjca.2017.10.004_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-154-1-201101040-00289","article-title":"Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation","volume":"154","author":"Freeman","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2017.10.004_bib18","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1093\/eurheartj\/ehq250","article-title":"Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W","volume":"31","author":"De Caterina","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2017.10.004_bib19","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1161\/01.CIR.92.10.2811","article-title":"Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries","volume":"92","author":"Gore","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.10.004_bib20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/01.CIR.94.5.957","article-title":"Cost-effectiveness of routine coronary angiography after acute myocardial infarction","volume":"94","author":"Kuntz","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2017.10.004_bib21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1097\/00005650-199111000-00007","article-title":"Functional status vs utilities in survivors of myocardial infarction","volume":"29","author":"Tsevat","year":"1991","journal-title":"Med Care"},{"key":"10.1016\/j.cjca.2017.10.004_bib22","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/00005650-200006000-00004","article-title":"One thousand health-related quality-of-life estimates","volume":"38","author":"Tengs","year":"2000","journal-title":"Med Care"},{"key":"10.1016\/j.cjca.2017.10.004_bib23","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1161\/01.STR.0000078311.18928.16","article-title":"Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis","volume":"34","author":"Eckman","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.cjca.2017.10.004_bib24","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/j.jacc.2008.01.042","article-title":"Balancing the risks of restenosis and stent thrombosis in bare-metal vs drug-eluting stents: results of a decision analytical model","volume":"51","author":"Garg","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib25","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1159\/000074814","article-title":"Functional capacity impairment in patients with coronary artery disease: prevalence, risk factors and prognosis","volume":"100","author":"Tenenbaum","year":"2003","journal-title":"Cardiology"},{"key":"10.1016\/j.cjca.2017.10.004_bib26","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s11606-014-2813-1","article-title":"Comparative-effectiveness of revascularization vs routine medical therapy for stable ischemic heart disease: a population-based study","volume":"29","author":"Wijeysundera","year":"2014","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.cjca.2017.10.004_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.cjca.2016.02.056","article-title":"Cost-effectiveness of left atrial appendage closure for stroke prevention in atrial fibrillation patients with contraindications to anticoagulation","volume":"32","author":"Saw","year":"2016","journal-title":"Canadian J Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib28","unstructured":"Ontario Drug Benefit (ODB) Program E-Formulary. Ontario Ministry of Health and Long Term Care, 2015. Available at: http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/drugs\/odbf_eformulary.aspx. Accessed November 28, 2017."},{"key":"10.1016\/j.cjca.2017.10.004_bib29","unstructured":"Ontario Case Costing Initiative. Available at: https:\/\/www.cadth.ca\/sites\/default\/files\/pdf\/CostingGuidance_draft22June2015.pdf. Accessed November 28, 2017."},{"key":"10.1016\/j.cjca.2017.10.004_bib30","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib31","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib32","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2017.10.004_bib33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.carrev.2014.08.009","article-title":"Polymer-free drug-eluting stent in unselected patient population: a single center experience","volume":"15","author":"Konigstein","year":"2014","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.cjca.2017.10.004_bib34","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib35","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.cjca.2014.09.011","article-title":"Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective","volume":"30","author":"Gandhi","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib36","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.cjca.2013.07.001","article-title":"Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy","volume":"29","author":"Tanguay","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2017.02.096","article-title":"Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: a nationwide long-term registry analysis from 2009 to 2014","volume":"235","author":"Sheikh Rezaei","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2017.10.004_bib38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2017.10.004_bib39","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17310772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X17310772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T22:31:54Z","timestamp":1535322714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X17310772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0828282X17310772"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2017.10.004","relation":{},"ISSN":["0828-282X"],"issn-type":[{"type":"print","value":"0828-282X"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2017.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}